Navigation Links
ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
Date:10/2/2009

IRVINE, Calif., Oct. 2 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will release third quarter 2009 financial results after market close on November 3, 2009. In conjunction, the Company will host a conference call at 5:00 p.m. Eastern Time to discuss these results and provide a pipeline update.

Date: Tuesday, November 3, 2009

Time: 5:00 p.m. Eastern Time

Conference call access:

Internet: www.istavision.com

Domestic dial-in: 800-510-9691

International dial-in: 617-614-3453

Passcode: 62898415

To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 52451599. This conference call also will be webcast live and archived on ISTA's website until December 3, 2009.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

SOURCE ISTA Pharmaceuticals, Inc.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
2. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
3. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
4. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
7. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
8. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
9. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... the necessity of health literacy within the technology advancement of diagnostic imaging. According to a ... majority of oncology patients undergo imaging screenings without understanding the nuanced risks associated with ... ... ... Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... , May 26, 2016 ... market growth is the emergence of new treatments. Cardax, ... therapies for osteoarthritis treatment. The therapy is expected to ... Arthritis Research UK is conducting studies to develop new ... study, where the genes involved in osteoarthritis are being ...
Breaking Medicine Technology:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... campaign returns for a third time to shed lights on the variety of topics ... and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed at ... stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight to ... industry leaders such as Bioness. , As patients feel increasingly concerned about ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... interest stories, courtesy of leaders in the nursing and health care industry. It ... leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
Breaking Medicine News(10 mins):